Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Emergent BioSolutions Inc. EBS

Set alert

Price alert · EBS

All alert types
6.62 USD +0.18 +2.80%

As of Nov 3, 11:35 AM ET

Bid
6.61 × 2
Ask
6.64 × 1
5.51 Day range 7.22
4.36 52-week range 14.06
YTD
-46.44%
1 year
-36.89%
Open
5.51
Prev close
6.44
Mkt cap
339.17M
Vol
1.14M
Avg vol
1.24M
EPS
-3.40
P/E
0.00
Div yield
0.00%
More statistics
Low
5.51
High
7.22
Forward P/E
2.73
Beta
1.57
Short ratio
4.54
Inst. own
60.02%
Dividend
0.00
Ex-div date
50-d avg
9.27
200-d avg
7.13
1y target
12.00

5D chart

Chart tools
Interval
1m5m15m30m

Signals (66)
NameTimeAgo
MACD: Sell SignalNov 3, 10:45 AM50 minutes ago
SMA: BearishNov 3, 10:35 AM1 hour ago
RSI: OverboughtNov 3, 9:55 AM1 hour ago
SMA: BullishNov 3, 9:35 AM2 hours ago
RSI: OverboughtNov 3, 9:35 AM2 hours ago
SMA: BullishNov 2, 3:55 PM19 hours ago
MACD: Buy SignalNov 2, 3:55 PM19 hours ago
RSI: OversoldNov 2, 3:10 PM20 hours ago
RSI: OversoldNov 2, 2:45 PM20 hours ago
RSI: OversoldNov 2, 1:55 PM21 hours ago
RSI: OversoldNov 2, 1:35 PM22 hours ago
SMA: BullishNov 2, 12:55 PM22 hours ago
SMA: BearishNov 2, 12:20 PM23 hours ago
MACD: Sell SignalNov 2, 12:20 PM23 hours ago
SMA: BearishNov 2, 11:55 AM23 hours ago
MACD: Buy SignalNov 2, 10:35 AM1 day ago
RSI: OversoldNov 2, 10:05 AM1 day ago
RSI: OversoldNov 2, 9:45 AM1 day ago
MACD: Sell SignalNov 2, 9:35 AM1 day ago
RSI: OversoldNov 2, 9:35 AM1 day ago

Newest 20 of 66.

Analyst view

Consensus: buy

Buy
Price target (mean) 12.00
Ratings (0m) 2 1 buy · 0 hold · 1 sell
  • Strong buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong sell1

Recommendation trend

  • This month 2
  • 1 month ago 2
  • 2 months ago 2

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

EBS analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.64-0.64 – -0.64-0.77+16.9%248.00M-10.3%1
Next quarter1.141.14 – 1.140.59+93.2%00.0%1
Current year-0.81308-1.00 – -0.62615-6.23+87.0%1.10B+4.6%2
Next year2.072.07 – 2.07-0.81308+354.0%1.09B-0.2%1

Upgrades and downgrades

The latest rating changes

EBS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 7, 2024BenchmarkMaintainedBuyBuy
Sep 13, 2024Rodman & RenshawReiteratedBuyBuy
Aug 22, 2024Rodman & RenshawInitiated—Buy
Aug 16, 2024BenchmarkReiteratedBuyBuy
Aug 9, 2024BenchmarkReiteratedBuyBuy
Jul 3, 2024BenchmarkReiteratedBuyBuy
Jul 2, 2024BenchmarkReiteratedBuyBuy
Jun 24, 2024BenchmarkReiteratedBuyBuy
Jun 21, 2024BenchmarkReiteratedBuyBuy
Jun 20, 2024BenchmarkMaintainedBuyBuy
Apr 11, 2024BenchmarkReiteratedBuyBuy
Mar 7, 2024BenchmarkUpgradeHoldBuy
Aug 29, 2023BenchmarkDowngradeBuyHold
May 31, 2023BenchmarkReiteratedBuyBuy
May 19, 2023BenchmarkReiteratedBuyBuy
Apr 10, 2023BenchmarkUpgradeHoldBuy
Mar 17, 2023JP MorganDowngradeNeutralUnderweight
Nov 10, 2022BenchmarkDowngradeBuyHold
Nov 9, 2022Chardan CapitalMaintained—Buy
Sep 12, 2022Cowen & Co.Maintained—Market Perform
May 4, 2022Wells FargoMaintained—Equal-Weight
Apr 29, 2022Chardan CapitalMaintained—Buy
Mar 10, 2022Wells FargoMaintained—Equal-Weight
Nov 10, 2021Chardan CapitalMaintained—Buy
Nov 8, 2021BenchmarkDowngradeBuyHold
May 5, 2021Argus ResearchDowngradeBuyHold
Apr 30, 2021Chardan CapitalMaintained—Buy
Apr 7, 2021BenchmarkInitiated—Buy
Feb 24, 2021Chardan CapitalUpgradeNeutralBuy
Feb 19, 2021Chardan CapitalDowngradeBuyNeutral